In:
Annals of the New York Academy of Sciences, Wiley, Vol. 1182, No. 1 ( 2009-12), p. 80-87
Abstract:
Interferon lambdas (IFN‐λ) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IFNs, but signal through a distinct receptor complex. The expression pattern for the IFN‐λ receptor is more cell specific than the widely distributed IFN‐α receptor, suggesting in vivo , IFN‐λ may have fewer side effects than IFN‐α, such as less hematologic toxicities. A PEGylated form of IFN‐λ (PEG‐rIL‐29) was well tolerated in animals and did not result in hematologic toxicity. Clinical data from initial studies of PEG‐rIL‐29 has demonstrated antiviral effects in patients with hepatitis C without producing hematologic toxicity. These preclinical and early clinical data support PEG‐rIL‐29 as a potential new therapeutic agent for treatment of patients with hepatitis C.
Type of Medium:
Online Resource
ISSN:
0077-8923
,
1749-6632
DOI:
10.1111/nyas.2009.1182.issue-1
DOI:
10.1111/j.1749-6632.2009.05241.x
Language:
English
Publisher:
Wiley
Publication Date:
2009
detail.hit.zdb_id:
2834079-6
detail.hit.zdb_id:
211003-9
detail.hit.zdb_id:
2071584-5
SSG:
11
Permalink